Abstract: This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.

Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.

Abstract: A mortar mixture for horizontal surfaces or as casting mortar in molds has at least 20% of the mortar mixture by volume being balls composed of expanded silica sand or expanded perlite with the balls being glazed and closed at the surface thereof and filled with air. The expanded perlite balls are mixed with binding agents, additives as binders, an air-void forming agent, chemical admixtures as liquefiers, quick-setting binders, or a combination thereof, and composed of polymers. The method for producing the mortar mixture is performed by sorting perlite sand into various grain sizes by a grading curve. Each individual grain size is then expanded in a trickling channel having multi-stage temperature zones so that the surface of the balls is glazed. The glazed, expanded perlite so produced are mixed together into a homogenous mixture by adding binding agents and cellulose, air-void forming agent, chemical admixtures or a combination thereof.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: A method for testing a high-pressure pump, particularly a high-pressure pump which is provided to inject fuel into a combustion engine, the method including filling the high-pressure pump with a fluid prior to switching it on.

Abstract: The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.

Abstract: Treatment of the wastewater from isophorone production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction. The invention relates to treatment of the wastewater from isophorone (IP) production comprising neutralization, filtration and a downstream chemical oxidation process and subsequent reduction.

Abstract: A safety module for an automation system including a communication interface, which is configured for a signal-transmitting connection to a communication system including an output interface, which is configured for a signal-transmitting connection to consumers, which can be attached downstream, and including a processing device which is connected to both interfaces and is configured for processing communication signals from the communication interface and for providing processing results as output signals at the output interface. The processing device is configured such that a safety-related output signal is provided at the output interface if a safety signal, which is contained in a communication signal, is present, and if at least two data records, which are respectively provided in a communication signal, are encoded differently and are directed at the processing device, conform with one another.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.

Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.

Abstract: A method is described for manufacturing a solenoid valve, in particular a fuel injector, the solenoid valve having a valve needle which is movably guided in the axial direction, a magnet core and an armature which is situated axially diametrically opposed to the magnet core, the armature being situated on the valve needle, the armature having a first base material and a first reinforcing element and the magnet core having a second base material and a second reinforcing element. The method has one method step. The first reinforcing element is applied to the first base material and/or the second reinforcing element is applied to the second base material during the method step with the aid of molten bath spraying or with the aid of cold gas spraying.

Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula(I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.

Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.